| Literature DB >> 31036003 |
Camila Shirota1, Sivakumar Balasubramanian2, Alejandro Melendez-Calderon3,4,5.
Abstract
BACKGROUND: There is growing interest in the use of technology in neurorehabilitation, from robotic to sensor-based devices. These technologies are believed to be excellent tools for quantitative assessment of sensorimotor ability, addressing the shortcomings of traditional clinical assessments. However, clinical adoption of technology-based assessments is very limited. To understand this apparent contradiction, we sought to gather the points-of-view of different stakeholders in the development and use of technology-aided sensorimotor assessments.Entities:
Keywords: Neurorehabilitation technologies; Outcome measures; Physical therapy; Rehabilitation; Sensorimotor assessments
Mesh:
Year: 2019 PMID: 31036003 PMCID: PMC6489331 DOI: 10.1186/s12984-019-0519-7
Source DB: PubMed Journal: J Neuroeng Rehabil ISSN: 1743-0003 Impact factor: 4.262
Structure of the online questionnaire. Refer to Additional file 1 for the specific questions (indicated by Qx)
| Section | Target professional background | Topics covered |
| Section I Demographics | All | • Gender (Q1) • Location (Q2) • Categorization: Patient/Non-patient (Q3) • Years of experience in rehabilitation (Q4) • Exposure to technology-aided assessments (Q5) • Profession (Q6) |
| Section II 1 Profession-specific questions | Clinicians | • Work environment & experience with technology (Q7-Q8) • Frequency of assessments with and without technology (Q9-Q11) • Interaction with engineers (Q12) |
| Engineers (research or medical industry) | • Familiarity with different technologies (Q13) • Interaction with clinicians and patients (Q14-Q15) • Perceptions about routine assessments (Q16) | |
| Neuroscientists | • Interaction with clinicians and patients (Q24-Q25) • Perceptions about routine assessments (Q26-Q26) • Perceptions about using neuroscience paradigms as clinical assessments (Q27-Q28) | |
| Hospital/clinic administrators | • Use of technology for rehabilitation and assessments (Q29-Q30) • Frequency of assessments in their institution (Q31) | |
| Medical Industry (non-engineering positions) | • Type of technology provided (Q32) • Market for technology-based assessments (Q33; Q35-Q36) • Effort put into technology-based assessments (Q34) | |
| Patients | • Rehabilitation environment (Q17) • Frequency of assessments with and without technology (Q18-Q19) • Perceived value of assessments (Q20) • Knowledge of results (Q21) • Types of technologies used (Q22-Q23) | |
| Section III Motivators, barriers and opinions on the future of technology-aided assessments | All | • Duration of ideal assessment (Q37) • Motivators for routine assessments with and without technology (Q38) • Level of detail required for different assessment purposes (Q39) • Major bottlenecks in technology-based assessments (Q40-Q41) • Focus for the next 5 years to promote technology-based assessments (Q42) • Open questions/comments (Q43-Q45) |
1Respondents that selected Policy maker, Insurance representative, or Other (free text) as their profession did not complete Section II
Categorization of professions in stakeholder groups for analysis
| Stakeholder category | Selected profession (Q6) |
| Clinician | - Medical doctor - Therapist (clinic-focused) - Therapist (research-focused) |
| Research Engineer | - Engineer (academic or non-profit institution research) |
| Basic Scientist | - Neuroscientist - Other (free text) with the keyword ( |
| Medical Industry | - Engineer (medical industry) - Manager (medical industry) - Sales representative of medical technologies - Other (medical industry) - Other (free text) with the keyword |
| Hospital Administrator | - Hospital / clinic administrator |
| Policy Maker | - Policy maker (e.g., work for a government organization) - Insurance representative |
| Patient | Receiving therapy due to a neuromuscular disorder (Q3). |
| Other | None of the above |
Fig. 1Geographic distribution of questionnaire respondents. Countries are shaded according to the number of respondents; the list of countries shows their relative representation. [Q2: What country do you live/work in?]
Fig. 2Respondent demographics per stakeholder group (left) [Q1: What is your gender?; Q6: What is your profession? (according to Table 2)] and years of experience in rehabilitation (right) [Q4: How many years of professional experience do you have in the field of rehabilitation? (Including: clinical work, research, technology development, sales, policy making, etc.)]
Interdisciplinary interactions between Clinicians, Engineers, Basic Scientists and Patients. [Q2, Q14, Q15, Q24, Q25: In your work, what kind of interactions have you had with: i) technology developers (Q12), ii) patients (Q14 & Q24) and iii) therapists (Q15 & Q25)?]
Fig. 3Types of technology provided by Medical Industry [Q32: What kind of technologies do you provide?]; note that selecting more than one category was possible. *Only respondents that selected “Manager (medical industry)”, “Sales representative of medical technologies” or “Other (medical industry)” as their profession (Q6) were asked this question
Fig. 4Use of technology at work by different stakeholders. [Clinicians: Q8: How often are these technologies used in your work (not restricted to assessments)?; Engineers (research and medical industry): Q13: How often are these technologies used in your work environment?]. *Only Medical Industry respondents that selected “Engineers (medical industry)” as their profession (Q6) were asked this question
Fig. 5Exposure to technology-aided assessments – observed (blue, dashed outline), used (yellow, dash-dotted outline), and developed (red, solid outline) – per stakeholder group: a Research Engineer, b Clinician (two participants stated ‘no experience’), c Medical Industry (two participants stated ‘no experience’), d Basic Scientist, e Other. Areas proportional to counts within group; adapted from diagrams generated with [7]. We show the percentages associated to respondents who have developed technology (i.e. developed, developed AND observed, developed AND used, developed AND observed AND used) [Q5: What kind of exposure have you had with technology-aided assessments?]
Frequency of sensorimotor assessments as predicted by Research Engineers, Medical Industry and Basic Scientists (yellow), as practiced by Clinicians (green), and as experienced by Patients (blue; results in percent respondents per group). Darker shades indicate higher percentages. [Q16, Q26: How often do you think therapists perform standard clinical assessments on a given patient during routine clinical practice? | Q10: How often do you (or your personnel) perform standard clinical assessments on a given patient during routine clinical practice? | Q11: How often do you (or your personnel) use any kind of technology to perform assessments on a given patient during routine clinical practice? | Q18: How often do you do clinical assessments during your therapy sessions | Q19: How often do your therapists use technological tools to assess you during therapy sessions?]
Clinician preference for different sensorimotor assessment methods (in percent Clinician respondents; n = 38). Darker shades indicate higher percentages. [Q9: How do you assess the sensorimotor ability of your patients?]
Motivators to perform and document assessments (1–Least Important, 3–Most Important). Darker shades indicate higher percentages. [Q38: What are the main motivators to perform and document results from routine assessments (standard clinical or technology-aided)?]
Minimum level of detail required in sensorimotor assessments for different objectives according to stakeholder groups (weighted rank per group). 1 – indicates activity-level assessments (low level of detail), while 4 – indicates assessment at the structural- and biological-levels (high level of detail). Darker shades indicate higher percentages. [Q39: In your opinion, which is the minimum level of detail needed in the quantification of sensorimotor problems for the following objectives?]
Interest in assessment tools by different groups as reported by Medical Industry (n = 15*). Darker shades indicate higher percentages. [Q33: What is the current interest in assessment tools?]
*Only Medical Industry (non-Engineers), i.e., respondents that selected entries different than “Engineer (medical industry)” as their profession (Q6), were asked this question
**To avoid confusion, the term “Researchers” is used here in a general sense
Preferred amount of time for sensorimotor assessments per patient per week (in percent respondents per group). Darker shades indicate higher percentages. [Q37: What is a reasonable amount of time for a sensorimotor assessment that has to be performed at least once a week (per patient) - from beginning of setup to end of undoing setup?]
*one participant did not answer this question
Importance of factors currently hindering the use of (standard and technology-aided) sensorimotor assessments in the clinical practice according to stakeholder groups (weighted rank per group). Darker shades indicate higher rank. [Q40: How much do issues in each of the following categories hinder the routine use of assessments (standard clinical or technology-aided) in the clinical practice?]
Importance of factors currently hindering the use of technology-aided sensorimotor assessments in the clinical practice according to stakeholder groups (weighted rank per group; rank: 1 = least important, 8 = most important). Darker shades indicate higher percentages. [Q41: What are the major bottlenecks in implementing technology-aided sensorimotor assessments in routine clinical practice?]
Importance of types of activities to do in the next 5 years to facilitate the use of new technologies and methodologies in the clinical practice according to stakeholder group (weighted rank per group). 1: lowest priority; 5: highest priority. Darker shades indicate higher percentages. [Q42: What type of activities should we do in the next 5 years to facilitate the use of new technologies and methodologies in clinical practice?]
Summary of open questions (Q44) and comments (Q45)
| Research Engineers | Questions |
• Will insurance companies be willing to reimburse for technology-aided assessment with the current level of standardization and output metrics? • How to combine diverse technologies and the lack of clarity on what exactly to measure? What is the way forward for both these issues? | |
| Comments | |
| • It seems that standardization, clinical use, and reimbursement mechanisms are a bit of a chicken and egg problem: standardization requires use, use requires reimbursement, and reimbursement requires standardization. | |
| Clinicians | Questions |
• How to interpret and standardize technical outcome parameters? • Why don’t technology developers collect more information from clinical therapists and patients? | |
| Comments | |
• There is a need for better access to affordable technology for clinical use. • An objective sensory measurement tool would be clinically useful. • Assessment must be reliable, meaningful, simple to administer and learn. • Technology failures cannot occur. We cannot use the time of clinicians and patients by using technically unreliable tools. | |
| Basic Scientists | Questions |
• What is really important to assess for clinicians, therapists, and patients? Are they aligned? • How do researchers developing outcome measures based on neuroscientific principles convince clinicians to trust and use these new tools? | |
| Comments | |
• • • There is a need for standardization and widespread implementation. | |
| Medical Industry | Comments |
| There are standard requirements of any measurement tool, e.g., validity, reliability, sensitivity to change, inter and intra-rater reliability, training. It is important that these are evaluated in a standardized way. | |
| Others | Questions |
| What is the best way to share current research outcomes for clinical therapists to be up-to-date on the latest findings? Such sharing of knowledge can advocate the gradual implementation of technology in clinical activities at different organizational levels. | |
| Patients | Comments |
|
|